Stock comparison
United Therapeutics
UTHR$24.13BHealthcare Market cap, Sector
Viatris
VTRS$19.39BHealthcare Market cap, Sector
Overall winner
United Therapeutics
UTHR 70 VTRS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
UTHR7wins
0winsVTRS
71B
F31
76B
F27
76B
F18
62C
F7
46D
F0
64C
F26
64C
F17
Side-by-side metrics
| Metric | UTHR | VTRS |
|---|---|---|
| Market cap | Winner: $24.13B | $19.39B |
| P/E (TTM) | 19.2x | - Winner |
| EV/EBIT | 15.2x | - Winner |
| ROIC (TTM) | Winner: 18.81% | 0.16% |
| Gross margin | Winner: 86.58% | 34.4% |
| Net margin | Winner: 40.61% | -2.04% |
| Revenue CAGR 5y | Winner: 17.22% | -5.44% |
| EPS CAGR 5y | Winner: 29.84% | -69.69% |
| Debt / Equity | Winner: - | 1.0x |
| Dividend yield | 0.0% | 2.8% Winner |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
UTHR leads on
- EPS CAGR 5y29.84%vs -69.69%+143%
- Revenue CAGR 5y17.22%vs -5.44%+132%
- Net margin40.61%vs -2.04%+105%
- Debt / Equity-vs 1.0x+100%
VTRS leads on
- EV/EBIT-vs 15.2x+180%
- P/E (TTM)-vs 19.2x+129%
- Dividend yield2.8%vs 0.0%+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.